Vistagen Therapeutics, Inc. filings document regulatory and corporate events for a Nasdaq-listed late clinical-stage biopharmaceutical company. Recent Form 8-K disclosures cover clinical program updates for fasedienol in the PALISADE social anxiety disorder program, FDA-related developments for refisolone under an IND application, and Regulation FD materials such as corporate presentations.
The company’s filings also record governance and capital-structure matters, including board departures, Audit Committee composition and Nasdaq listing-rule compliance, employee retention awards under the Amended and Restated 2019 Omnibus Equity Incentive Plan, and workforce and cash-management actions tied to clinical-development priorities.
Vistagen Therapeutics, Inc. reported topline data from an exploratory, three-arm, randomized, double-blind, placebo-controlled Phase 2 study (N=61) of intranasal fasedienol for the acute treatment of social anxiety disorder during a public speaking challenge, comparing two 3.2 µg doses ten minutes apart with a single 3.2 µg dose and placebo.
The study met its safety objective, with repeat dosing showing safety and tolerability comparable to single-dose administration and no new safety findings. On the primary endpoint, LS mean change in Subjective Units of Distress (SUDS) from baseline to challenge, pooled fasedienol reduced SUDS by 15.0 versus 6.8 for placebo, but between-group differences were not statistically significant. In a prespecified subgroup with very severe social anxiety (Liebowitz Social Anxiety Scale ≥95), pooled fasedienol showed a larger SUDS reduction of 16.2 versus 1.6 for placebo with nominal p=0.04. Responder rates on CGI-I and PGI-C were directionally higher for fasedienol, with repeat-dose CGI-I responders at 47% versus 19% for placebo. An exploratory analysis of anticipatory anxiety found pooled fasedienol cut SUDS by 13.8 versus 0.9 for placebo (nominal p=0.03), with repeat dosing at 19.3 (p=0.01). These exploratory findings, which include nominally statistically significant effects in very severe patients, will inform upcoming discussions with the FDA about a potential registrational pathway for fasedienol, subject to the cautions and risks described.
Vistagen Therapeutics, Inc. reports that Nasdaq has granted a 180-day extension, until February 1, 2027, to regain compliance with the $1.00 per share Minimum Bid Price Requirement for its common stock to remain listed on the Nasdaq Capital Market.
The extension does not immediately affect the stock’s listing, which remains fully effective. Vistagen has informed Nasdaq it intends to cure the deficiency within the extension period. If compliance is not restored by that deadline, the common stock would be subject to delisting, and any appeal to a Nasdaq Hearing Panel is not assured of success.
Vistagen Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on September 10, 2026 on three items: electing four continuing directors, a non-binding advisory vote on Named Executive Officer compensation, and ratification of KPMG LLP as independent auditor for the fiscal year ending March 31, 2027.
Holders of common stock at the July 22, 2026 record date, when 44,376,911 shares were outstanding, are entitled to one vote per share. The board currently has six members and will decrease to four after two directors do not stand for re-election, while a search is underway for additional independent candidates. The proxy describes director fees, heavy use of stock options in director and executive pay, a clawback policy, insider-trading and anti-hedging rules, and a prior Say-on-Pay vote that received over 97% support. For fiscal 2026, no performance-based cash bonuses or salary increases were granted to NEOs, though certain newer executives received retention bonuses and inducement option awards.
Williamson Douglas J reported acquisition or exercise transactions in this Form 4 filing.
Vistagen Therapeutics director Douglas J. Williamson received a grant of 40,826 stock options on July 29, 2026, each exercisable at $0.2433 per share for common stock. The options, granted in connection with his appointment to the Board under the company’s 2019 equity plan, vest in three equal annual installments beginning one year after grant and expire on July 29, 2036. Following this award, he holds 40,826 options, and no sales or purchases of common shares were reported.
Vistagen Therapeutics, Inc. filed a Form 3 initial statement of beneficial ownership for Douglas J Williamson, who is identified as a director of the company. The filing reports no transactions and does not list any equity holdings or derivative positions for him.
Vistagen Therapeutics, Inc. appointed Douglas J. Williamson, M.D. to its Board of Directors on July 29, 2026. Upon joining the board, he received stock options under the Director Compensation Plan to purchase up to 40,826 shares of common stock at an exercise price of $0.2433 per share, equal to the closing price on his appointment date. The options have a ten-year term and vest in equal annual installments over a three-year period beginning on the one-year anniversary of the Effective Date, becoming fully vested on the three-year anniversary. He will also receive annual cash compensation and additional equity awards under the plan.
Vistagen and Dr. Williamson entered into an Indemnification Agreement under which the company will indemnify him to the fullest extent permitted under Nevada law and advance certain expenses related to covered proceedings. Vistagen describes itself as a late clinical-stage biopharmaceutical company developing intranasal pherine product candidates, including fasedienol in U.S. Phase 3 development for social anxiety disorder and, in Phase 2 development, itruvone for major depressive disorder and refisolone for vasomotor symptoms due to menopause.
Vistagen Therapeutics Chief Legal Officer Reid G. Adler increased his holdings through the company’s employee stock purchase plan. Adler acquired 36,818 shares of common stock on June 30, 2026 at an average price of $0.1921 per share, pursuant to Vistagen’s 2019 Employee Stock Purchase Plan.
This compensation-related transaction is classified as a grant or award acquisition and was exempt under Rule 16b-3. Adler purchased the maximum amount permitted under the plan and now directly owns 60,868 shares of Vistagen common stock.
Tressler Nick B. reported acquisition or exercise transactions in this Form 4 filing.
Vistagen Therapeutics, Inc. Chief Financial Officer Nick B. Tressler received 11,712 shares of common stock on June 30, 2026 through the company’s 2019 Employee Stock Purchase Plan at $0.1921 per share. Following this compensation-related grant, he directly holds 11,712 shares.
Vistagen Therapeutics, Inc. President and CEO Shawn Singh acquired shares of the company through an employee stock purchase program. He received 36,818 shares of common stock at a purchase price of $0.1921 per share under Vistagen's 2019 Employee Stock Purchase Plan, as amended. This plan-related acquisition is classified as a grant or award and is exempt under Rule 16b-3.
Following this acquisition, Singh directly holds 54,846 shares of Vistagen common stock. The filing also reports an additional 20,875 shares of common stock held indirectly by The 1997 Singh Family Trust U/R/D 05/29/1997, reflecting family trust ownership separate from his direct holdings.
Vistagen Therapeutics reported topline results from its PALISADE-4 Phase 3 trial of intranasal fasedienol for social anxiety disorder. In the full study population of 238 adults, fasedienol did not meet the primary endpoint, with a least squares mean SUDS score change of -9.5±1.7 versus -11.4±1.7 for placebo, a difference of 1.9 (p=0.427). Secondary endpoints also showed no treatment difference.
Safety and tolerability were favorable and consistent with prior placebo-controlled trials. In a post-hoc subgroup of 123 patients with very severe social anxiety (baseline LSAS ≥95), fasedienol showed a nominally statistically significant SUDS improvement of -12.8±3.4 versus -3.7±3.4 for placebo, a difference of -9.1 (p=0.036). Vistagen plans to meet with the FDA to discuss a potential registrational path focused on overall treatment of social anxiety disorder over time, supported by a planned multi-dose Phase 3 trial using LSAS as the primary endpoint and confirmatory evidence from the broader PALISADE program. The company continues to expect its cash resources to fund operations into 2027.